Repligen Corporation is a pioneer in bioprocessing technologies, playing a crucial role in the manufacturing of biological drugs globally. With a product lineup that includes Protein A ligands essential for drug purification, innovative chromatography columns like OPUS, and a range of filtration devices, Repligen supports the biopharmaceutical industry's need for high-quality drug production. Their offerings extend to ELISA test kits and process analytics products, catering to life sciences, diagnostics, and biopharmaceutical companies. Founded in 1981 and based in Waltham, Massachusetts, Repligen is committed to advancing biomanufacturing with its collaborative and innovative solutions.
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not…
Pre-Market Stock Futures: Futures are trading mixed, with the Nasdaq getting hammered after a gangbuster start to the first full trading week of the third quarter. All of the major indices finished…
Wednesday's top analyst upgrades and downgrades included Array Technology, Blink Charging, Carnival, Carrier Global, DocuSign, Fox, Marathon Petroleum, Occidental Petroleum, PagSeguro Digital, Paramount Global, Salesforce, Viking Therapeutics and Williams Companies.
Thursday's top analyst upgrades and downgrades included Amgen, Archer Daniels Midland, Blackstone, Bloom Energy, Carnival, Chevron, Danaher, EQT, KKR, Nike, PACCAR, Plug Power, PulteGroup, QuantumScape and RingCentral.
Tuesday's top analyst upgrades and downgrades included Ally Financial, CarMax, Dominion Energy, Dynatrace, Exelon, GigaCloud Technology, Gilead Sciences, Intuit, KKR, Lowe’s Companies, Morgan Stanley and Tesla.
For health care investors, 2020 looks like a potentially good year after an especially fruitful JPMorgan Healthcare Conference this past week.
